Mosunetuzumab: First Approval

Mosunetuzumab: First Approval

Mosunetuzumab (Lunsumio ® ), an anti-CD20/CD3 T-cell engaging bispecific antibody, is being developed by Roche for the treatment of relapsed or refractory follicular lymphoma. Mosunetuzumab was recently conditionally approved in the EU for the treatment of relapsed or refractory follicular lymphoma...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drugs (New York, N.Y.) N.Y.), 2022-07, Vol.82 (11), p.1229-1234
1. Verfasser: Kang, Connie
Format: Artikel
Sprache:eng
Schlagworte:
AdisInsight Report
Antibodies
Apoptosis
Bispecific antibodies
CD20 antigen
CD3 antigen
Cytokines
Drug dosages
Internal Medicine
Lymphocytes T
Lymphoma
Medical prognosis
Medicine
Medicine & Public Health
Monoclonal antibodies
Neutropenia
Patients
Pharmacology/Toxicology
Pharmacotherapy
Targeted cancer therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Mosunetuzumab (Lunsumio ® ), an anti-CD20/CD3 T-cell engaging bispecific antibody, is being developed by Roche for the treatment of relapsed or refractory follicular lymphoma. Mosunetuzumab was recently conditionally approved in the EU for the treatment of relapsed or refractory follicular lymphoma in adults who have received at least two prior systemic therapies. This article summarizes the milestones in the development of mosunetuzumab leading to this first approval for relapsed or refractory follicular lymphoma.
ISSN:0012-6667
1179-1950
DOI:10.1007/s40265-022-01749-5